Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orchard Therapeutics Ltd.

www.orchard-tx.com

Latest From Orchard Therapeutics Ltd.

Oxford Biomedica, Microsoft Pact Aims At Better, Cheaper Lentiviral Vectors

Oxford Biomedica and Microsoft have joined forces to improve the yield and quality of next-generation gene therapy vectors using the cloud and machine learning, the UK gene and cell therapy company's chief business officer tells Scrip.

Artificial Intelligence Business Strategies

Gene Therapy Investment At All Time High, Commercialization Challenges Noted

Investor appetite for cell and gene therapy companies has skyrocketed during the past year. However, storm clouds may gather as manufacturing and reimbursement challenges remain.

Regenerative Medicine Financing

Patience Is A Virtue For French VC Kurma

Thierry Laugel, managing partner of the Paris-based financiers, tells Scrip about the virtues of its 'company creation model,' giving innovative ideas time to mature rather than rushing to the market.

Financing Rare Diseases

Start-Up Quarterly Statistics: Q3 Financings Slump Despite Large Gossamer Series B, Big Rubius IPO

Third quarter biopharma start-up financing activity decreased from the record-breaking Q2. A review of biopharma start-up dealmaking and financing activity from July through September 2018, based on data from Strategic Transactions.

Deals StartUps and SMEs
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Immune Disorders
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Orchard Therapeutics Ltd.
  • Senior Management
  • Mark Rothera, Pres. & CEO
    Frank Thomas, CFO & CBO
    Andrea Spezzi, MD, CMO
    Bobby Gaspar, MD, CSO
    Adrien Lemoine, SVP, Bus. Dev. & Alliance Mgmt.
  • Contact Info
  • Orchard Therapeutics Ltd.
    Phone: 203 384 6700
    108 Cannon St.
    London, EC4N 6EU
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register